查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971570

自动化血液处理设备市场：按产品类型、组件、操作模式、最终用户和应用划分 - 全球预测（2026-2032 年）

Automated Blood Processing Equipment Market by Product Type, Component, Mode Of Operation, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自动化血液处理设备市场价值将达到 545.5 亿美元，到 2026 年将成长至 591 亿美元，到 2032 年将达到 966.2 亿美元，复合年增长率为 8.50%。

主要市场统计数据
基准年 2025 545.5亿美元
预计年份：2026年 591亿美元
预测年份 2032 966.2亿美元
复合年增长率 (%) 8.50%

对自动化血液处理系统进行策略性概述，重点在于改变输血工作流程的临床因素、监管压力、互通性要求和技术融合。

自动化血液处理系统正处于临床需求、营运效率和设备创新三者交会的十字路口。医院、血库、诊断检查室和研究机构面临越来越大的压力，需要提高处理能力、减少人为错误，并增强从血液采集到成分製备的整个工作流程的可追溯性。为此，供应商正在推动自动化技术的发展，以支援全血、血浆、血小板和细胞疗法的稳定处理，同时满足严格的安全标准和监管要求。

透过识别自动化、人工智慧驱动的分析、远端监控、供应链弹性和临床检验的变革性变化，这些要素正在共同重新定义全球血液处理操作。

自动化血液处理环境正因多种因素的共同作用而快速发展。首先，机器人、感测器和使用者介面技术的成熟使得设备能够以可重复的品质执行复杂的血液分离任务，从而减少人为操作的差异并提高处理能力。同时，流程自动化、数据分析和数位化追溯的软体创新正在改变价值提案，使其从独立设备转向支援端到端工作流程的整合解决方案。

评估 2025 年美国关税对供应链、资本投资决策、跨境采购、零件采购以及整个价值链价格结构的累积影响。

美国将于2025年实施的关税调整正在影响依赖进口零件和设备的企业的采购趋势、供应商选择和营运规划。设备製造商和采购商必须考虑到岸成本的变化、供应商合约的重组以及零件交付可能出现的延误，所有这些都会影响资本支出週期和备件供应。为此，各企业正在重新审视筹资策略，以平衡成本、品质和前置作业时间。

透过产品类型、组件类别、最终用户概况、操作模式和临床应用领域等关键细分洞察，可以影响购买行为、服务模式和投资回报率指标。

详细的細項分析揭示了临床优先事项和营运需求如何影响不同设备和服务类别的采购选择。产品类型的差异，例如自动离心机、细胞分离系统、血浆分离系统和全血处理系统，决定了买家优先考虑的技术规格，包括处理能力、无菌控制和整合终点。同时，耗材、配件、设备和软体/服务等组件的考量决定了持续的成本结构，并透过专有耗材生态系统影响供应商锁定。

区域趋势和实施模式（北美和南美、欧洲、中东和非洲以及亚太地区）正在塑造监管协调、偿还途径和在地化商业化策略。

区域趋势反映了监管环境、报销机制和普及速度的差异，决定了技术的传播范围和方式。在美洲，大规模综合医疗保健系统和集中式血液服务往往主导采购决策，优先考虑规模、互通性和已证实的临床疗效。在欧洲、中东和非洲，法规结构和基础设施成熟度各不相同，协调工作和区域报销政策决定了打入市场策略和经销伙伴。在亚太地区，主要大都市地区的快速普及正在推进，同时国内製造业和对区域卓越中心的投资也不断增长。

竞争格局及主要企业洞察：涵盖创新组合、策略联盟、製造地、售后服务与市场进入差异化策略

竞争格局的核心在于设备设计、耗材生态系统、软体驱动的工作流程、服务交付的创新。主要企业透过投资自动化可靠性、易用性和检验的临床通讯协定来脱颖而出，从而降低医院和血站采用这些技术的门槛。与临床机构和研究中心建立策略合作伙伴关係，正在加速证据的产生并拓展应用场景，尤其是在细胞疗法和富血小板血浆处理等新兴应用领域。

对产业领导者的具体建议：策略采购、模组化产品设计、监管合作、临床证据产生以及促进推广和降低风险的商业模式。

产业领导者应采取一系列切实可行、基于实证的措施，在降低营运风险的同时加快部署速度。首先，应优先考虑互通性，采用开放的通讯标准，并设计和选择已验证可与实验室资讯系统和电子健康记录系统整合的设备。这将减少部署过程中的摩擦，并确保工作流程的连续性。其次，应投资于模组化产品架构和检验的用例库，以实现分阶段部署，并最大限度地减少临床检验期间的中断。

为了确保分析的严谨性和可重复性，我们系统性地结合了以下调查方法：与专家进行初步咨询、有针对性的二次调查、三角测量通讯协定和品质保证程序。

研究途径结合了结构化的专家参与和有针对性的二次检验，以确保研究结果的平衡性和可重复性。主要资讯来源包括与输血医学临床负责人、采购经理、检查室营运经理和设备工程师的咨询，以深入了解工作流程需求、检验挑战和服务期望等方面的细微观点。基于这些访谈提出的假设，会根据已记录的证据和技术规格进行检验。

全面整合，从临床、製造和政策领域的相关人员中提取营运见解、策略重点、投资槓桿以及中短期行动计画。

本分析整合了营运、监管和商业层面，为考虑实施自动化血液处理系统的相关人员提供统一的观点。关键要点包括：在技术选择过程中，必须平衡即时工作流程改善与长期互通性、可维护性和实证实践。基于模组化检验和稳健的供应商伙伴关係制定实施计画的机构，将最大限度地减少干扰，并确保在一致性和处理能力方面实现预期改进。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：自动化血液处理设备市场：依产品类型划分

  • 自动离心分离器
  • 细胞分离系统
  • 电浆分离系统
  • 全血处理系统

第九章 自动化血液处理设备市场：依组件划分

  • 耗材和配件
  • 装置
  • 软体和服务

第十章：自动化血液处理设备市场：依操作模式划分

  • 全自动
  • 半自动

第十一章：自动化血液处理设备市场：以最终用户划分

  • 血库
  • 诊断检查室
  • 医院
  • 研究机构

第十二章 自动化血液处理设备市场：依应用领域划分

  • 细胞疗法
  • 透析
  • 血液疗法
  • 富血小板血浆（PRP）製备

第十三章：自动化血液处理设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：自动化血液处理设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 自动化血液处理设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国自动化血液处理设备市场

第十七章：中国自动化血液处理设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Grifols SA
  • Haemonetics Corporation
  • Horiba Ltd.
  • Immucor, Inc.
  • Mindray Medical International Limited
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-535C62918B29

The Automated Blood Processing Equipment Market was valued at USD 54.55 billion in 2025 and is projected to grow to USD 59.10 billion in 2026, with a CAGR of 8.50%, reaching USD 96.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 54.55 billion
Estimated Year [2026] USD 59.10 billion
Forecast Year [2032] USD 96.62 billion
CAGR (%) 8.50%

Strategic overview of automated blood processing equipment highlighting clinical drivers, regulatory pressures, interoperability demands, and technological convergence transforming transfusion workflows

Automated blood processing equipment stands at the intersection of clinical need, operational efficiency, and device innovation. Hospitals, blood banks, diagnostic laboratories, and research institutes face increasing pressure to improve throughput, reduce manual handling errors, and strengthen traceability across blood collection and component preparation workflows. In response, vendors are advancing automation to support consistent processing of whole blood, plasma, platelets, and cellular therapies while addressing stringent safety and regulatory expectations.

Stakeholders now evaluate technology not only for its hardware capabilities but for its ability to integrate with laboratory information systems, electronic health records, and cloud analytics platforms. This emphasis on interoperability elevates software and services as critical components of value propositions. At the same time, consumables and accessories remain central to operational continuity and recurring revenue models. As a result, procurement decisions increasingly hinge on lifecycle costs, service agreements, and the depth of evidence supporting clinical outcomes.

Transitioning from manual to automated workflows requires coordinated clinical validation, staff training, and change management. Institutions that plan for phased deployment, proactive quality management, and stakeholder alignment can accelerate adoption while safeguarding patient safety. Consequently, strategic clarity around technology roadmaps and vendor commitments is now a prerequisite for successful implementation and long-term operational resilience.

Identifying transformative shifts in automation, AI-enabled analytics, remote monitoring, supply chain resilience, and clinical validation that are collectively redefining blood processing operations worldwide

The landscape for automated blood processing is evolving rapidly under several converging forces. First, technological maturation in robotics, sensors, and user interfaces has enabled devices to perform complex fractionation tasks with reproducible quality, reducing manual variability and improving throughput. Concurrently, software innovations-particularly in process automation, data analytics, and digital traceability-are shifting the value proposition from standalone instruments to integrated solutions that support end-to-end workflows.

Regulatory expectations and clinical evidence demands have intensified, prompting manufacturers to design devices that facilitate validation, auditability, and compliance. In parallel, clinical programs such as cell therapy and expanded platelet-rich plasma applications are driving demand for equipment capable of precise, sterile processing with minimal human intervention. Supply chain resilience has also risen in priority; institutions now evaluate manufacturers on the stability of their consumable supply, geographic manufacturing footprint, and contingency planning.

Finally, consolidation and partnership models between device producers, diagnostic laboratories, and healthcare providers are accelerating. These collaborations aim to combine clinical expertise, distribution reach, and service capabilities to reduce time-to-market and improve post-sale support. Taken together, these shifts are not incremental; they are reframing vendor selection, procurement timing, and long-term service relationships across healthcare organizations.

Assessing the cumulative impact of United States tariffs 2025 on supply chains, capital investment decisions, cross-border procurement, component sourcing, and pricing structures across the value chain

The United States tariff adjustments introduced in 2025 are affecting procurement dynamics, supplier selection, and operational planning for institutions that depend on imported components and instruments. Equipment manufacturers and buyers must now account for altered landed costs, reconfigured supplier contracts, and potential delays in component delivery, all of which influence capital expenditure cycles and spare-parts availability. In response, organizations are reassessing sourcing strategies to balance cost, quality, and lead time.

Manufacturers with diversified production footprints and regional assembly capabilities can mitigate tariff exposure and maintain service levels. At the same time, buyers are placing greater emphasis on total cost of ownership evaluations that incorporate duties, logistics risk, and aftermarket service resilience. Transitional strategies include renegotiating long-term supply agreements, increasing local inventory buffers for critical consumables, and qualifying alternative component suppliers to reduce single-source vulnerabilities.

Regulatory and procurement teams should also anticipate that tariff-driven pricing shifts could accelerate interest in domestically produced solutions or in products assembled closer to end markets. As a result, capital planning and vendor engagement must become more agile, with provisions for scenario modeling and contingency financing. Ultimately, the tariff environment is prompting a strategic recalibration of supply chain architecture and procurement policies in the short and medium term.

Key segmentation insights across product types, component categories, end-user profiles, modes of operation, and clinical applications that influence purchasing behavior, service models, and ROI metrics

A granular understanding of segmentation reveals how clinical priorities and operational requirements drive procurement choices across distinct device and service categories. Product type differentiation between Automated Centrifuges, Cell Separation Systems, Plasma Separation Systems, and Whole Blood Processing Systems shapes the technical specifications buyers prioritize, such as throughput, sterility controls, and integration endpoints. Meanwhile, component considerations across Consumables & Accessories, Instruments, and Software & Services determine recurring cost profiles and influence vendor lock-in due to proprietary consumable ecosystems.

End-user characteristics vary substantially between Blood Banks, Diagnostic Laboratories, Hospitals, and Research Institutes, with each cohort valuing different performance attributes; for example, blood banks emphasize donor throughput and component yield stability, diagnostic laboratories prioritize traceability and integration with LIS, hospitals demand compact footprint and service responsiveness, and research institutes prioritize flexibility for experimental protocols. Mode of operation distinctions-Fully Automated versus Semi Automated-further inform workflow redesign, staffing implications, and training needs, with fully automated systems reducing hands-on time but requiring higher upfront validation.

Application-specific demands across Cell Therapy, Dialysis, Hemotherapy, and Platelet Rich Plasma Preparation introduce specialized validation, sterility, and regulatory requirements that influence design choices and commercial positioning. Manufacturers that align product roadmaps with these layered segmentation insights can craft clearer value propositions, optimize aftermarket packages, and design commercial models aligned with each buyer persona.

Regional dynamics and adoption patterns across Americas, Europe Middle East & Africa, and Asia-Pacific shaping regulatory harmonization, reimbursement pathways, and localized commercialization strategies

Regional dynamics reflect differing regulatory regimes, reimbursement landscapes, and adoption curves that shape where and how technologies gain traction. In the Americas, procurement decisions are often driven by large integrated health systems and centralized blood services that prioritize scale, interoperability, and proven clinical outcomes. Europe, Middle East & Africa present a mosaic of regulatory frameworks and infrastructure maturity levels, where harmonization efforts and localized reimbursement policies dictate market entry strategies and distribution partnerships. Asia-Pacific exhibits rapid adoption in major metropolitan centers alongside growing investment in domestic manufacturing and regional centers of excellence.

These geographic nuances affect logistical planning, training models, and service networks. For example, regions with centralized blood services can adopt standardized protocols more rapidly, enabling faster roll-out of automated solutions, whereas diverse regulatory contexts require tailored evidence packages and iterative local validation. Manufacturers that invest in regional training hubs, multilingual clinical support, and localized spare-parts stocking can reduce implementation friction and improve customer satisfaction.

Moreover, regional procurement practices influence commercial structures; some markets favor capital purchase models while others increasingly evaluate managed-service or reagent-as-a-service arrangements. Understanding these distinctions is essential to designing scalable market entry strategies and sustainable after-sales programs across the Americas, Europe Middle East & Africa, and Asia-Pacific.

Competitive landscape and key company insights covering innovation portfolios, strategic partnerships, manufacturing footprints, aftermarket services, and go-to-market differentiation strategies

The competitive environment centers on innovation in instrument design, consumable ecosystems, software-enabled workflows, and service delivery. Leading companies differentiate through investments in automation reliability, ease of use, and validated clinical protocols that lower the barrier to adoption for hospitals and blood centers. Strategic partnerships with clinical institutions and research centers accelerate evidence generation and expand use cases, particularly in emerging applications like cell therapy and platelet-rich plasma processing.

Manufacturers that prioritize modular architectures and open interfaces position themselves favorably for integration into hospital and laboratory IT ecosystems. Aftermarket services, including rapid spare-part fulfillment, remote diagnostics, and subscription-based consumable programs, are increasingly critical levers for customer retention and recurring revenue. Additionally, localized manufacturing and regional distribution partnerships offer a competitive edge in markets sensitive to tariff fluctuations and logistics disruption.

New entrants face a high bar for clinical validation and scale, but they can compete by focusing on niche applications or novel process efficiencies. Established players, in contrast, can invest in incremental innovations and global service networks to defend market positions. Ultimately, successful companies combine product excellence with robust clinical evidence, predictable service models, and clear total-cost-of-ownership narratives.

Actionable recommendations for industry leaders on strategic sourcing, modular product design, regulatory engagement, clinical evidence generation, and commercial models to accelerate adoption and mitigate risk

Industry leaders should adopt a set of pragmatic, evidence-driven actions to accelerate adoption while mitigating operational risk. First, prioritize interoperability by designing or selecting devices with open communication standards and proven integration with laboratory information systems and electronic health records; doing so reduces implementation friction and preserves workflow continuity. Second, invest in modular product architectures and validated use-case libraries that allow phased deployment, minimizing disruption during clinical validation.

Third, strengthen supply chain resilience by diversifying component sources, maintaining regional inventory buffers for critical consumables, and establishing contingency plans for cross-border disruptions. Fourth, align commercial models to customer needs by offering flexible procurement options, including managed-service contracts, reagent-subscription programs, and bundled validation support that lower upfront barriers for buyers. Fifth, accelerate clinical acceptance through targeted evidence generation programs, peer-led training, and published real-world use cases that demonstrate clinical and operational advantages.

Finally, embed continuous service improvement via remote monitoring, predictive maintenance, and outcome-linked service metrics to enhance customer satisfaction and reduce downtime. Executed in concert, these measures create a compelling value proposition for buyers while reducing the risk and friction associated with technology transitions in critical blood processing workflows.

Research methodology detailing a systematic blend of primary expert consultations, targeted secondary research, triangulation protocols, and quality assurance procedures to ensure analytical rigor and reproducibility

The research approach combined structured primary engagement with subject-matter experts and targeted secondary validation to ensure balanced, reproducible findings. Primary input included consultations with clinical leaders in transfusion medicine, procurement executives, laboratory operations managers, and device engineers to capture nuanced perspectives on workflow requirements, validation pain points, and service expectations. These interviews informed hypotheses that were subsequently tested against documentary evidence and technical specifications.

Secondary research encompassed regulatory submissions, peer-reviewed clinical literature, product manuals, and publicly available company disclosures to verify claims and identify technology trends. Data synthesis relied on triangulation protocols to reconcile differing perspectives and to surface consistent themes across stakeholders. Quality assurance procedures included cross-review by independent analysts and iterative validation with domain experts to ensure methodological transparency.

Where possible, findings emphasized observable developments-such as adoption patterns, integration demands, and procurement behaviors-while avoiding speculative projections. The methodology prioritized traceable sources and repeatable techniques so that institutions can replicate the analytic steps for their specific contexts, ensuring that strategic decisions rest on a defensible evidence base.

Concluding synthesis that distills operational implications, strategic priorities, investment levers, and short-to-medium term action plans for stakeholders across clinical, manufacturing, and policy domains

The analysis synthesizes operational, regulatory, and commercial dimensions to create a unified perspective for stakeholders navigating automated blood processing adoption. The primary implication is that technology selection must balance immediate workflow gains with longer-term interoperability, serviceability, and evidence generation commitments. Institutions that plan deployments around modular validation and robust supplier partnerships will minimize disruption and capture the expected improvements in consistency and throughput.

Strategic priorities should include investing in staff training, aligning procurement practices with lifecycle cost assessments, and developing clinical validation plans that produce publishable outcomes. For manufacturers, the path forward involves deepening integration capabilities, expanding service offerings, and supporting regional manufacturing or distribution to minimize tariff and logistics exposure. Collaboration between providers and device makers-centered on shared protocols and outcome measurement-will accelerate real-world adoption and build trust among clinical users.

In closing, stakeholders that act deliberately-anchoring decisions to operational readiness, evidence requirements, and resilient supply strategies-will be best positioned to realize the clinical and economic benefits of automation in blood processing while minimizing implementation risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated Blood Processing Equipment Market, by Product Type

  • 8.1. Automated Centrifuges
  • 8.2. Cell Separation Systems
  • 8.3. Plasma Separation Systems
  • 8.4. Whole Blood Processing Systems

9. Automated Blood Processing Equipment Market, by Component

  • 9.1. Consumables & Accessories
  • 9.2. Instruments
  • 9.3. Software & Services

10. Automated Blood Processing Equipment Market, by Mode Of Operation

  • 10.1. Fully Automated
  • 10.2. Semi Automated

11. Automated Blood Processing Equipment Market, by End User

  • 11.1. Blood Banks
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Automated Blood Processing Equipment Market, by Application

  • 12.1. Cell Therapy
  • 12.2. Dialysis
  • 12.3. Hemotherapy
  • 12.4. Platelet Rich Plasma Preparation

13. Automated Blood Processing Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automated Blood Processing Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automated Blood Processing Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automated Blood Processing Equipment Market

17. China Automated Blood Processing Equipment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. bioMerieux SA
  • 18.8. Danaher Corporation
  • 18.9. F. Hoffmann-La Roche Ltd
  • 18.10. Grifols S.A.
  • 18.11. Haemonetics Corporation
  • 18.12. Horiba Ltd.
  • 18.13. Immucor, Inc.
  • 18.14. Mindray Medical International Limited
  • 18.15. Siemens Healthineers AG
  • 18.16. Sysmex Corporation
  • 18.17. Terumo Corporation
  • 18.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY AUTOMATED CENTRIFUGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY WHOLE BLOOD PROCESSING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY HEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PLATELET RICH PLASMA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 117. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 135. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. G7 AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 141. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA AUTOMATED BLOOD PROCESSING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)